The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
NCT ID: NCT00857350
Last Updated: 2013-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2008-06-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%.
2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)
NCT00933595
Immunologic Control of Drug Resistant HIV
NCT00053404
Pharmacotherapy for HIV Infected Patients With Alcohol Problems
NCT00854230
Evaluation and Monitoring of Patients With HIV Infectionn
NCT00557570
A Study of the Long-Term Outcomes of HIV-Positive Patients
NCT00000932
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV+, opiod dependent
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Opioid dependent
* Receiving methadone or buprenorphine for at least one month
Exclusion Criteria
* current dementia;
* inability to read or understand English
* inability to provide written informed consent
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Fiellin
Associate Professor of Medicine, Investigative Medicine and Public Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Fiellin, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Jeanette Tetrault, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University Hospital
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med. 2013 Mar-Apr;7(2):102-7. doi: 10.1097/ADM.0b013e31827f9bdf.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0709003082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.